

ACC-i2 with TCT

PATIENT AWARENESS OF SUSTAINED COMMITMENT TO CLOPIDOGREL USE AFTER PERCUTANEOUS CORONARY INTERVENTION FOR TREATMENT OF CORONARY HEART DISEASE IN THE CONTEMPORARY ERA

i2 Poster Contributions
McCormick Place South, Hall A
Saturday, March 24, 2012, 9:30 a.m.-Noon

Session Title: Adjunct Pharmacology
Abstract Category: 16. PCI - DES (clinical/outcomes)
Presentation Number: 2536-587

Authors: *M. Fuad Jan, Harold Elias, Naoyo Mori, Hina Mahboob, Anjan Gupta, Tanvir Bajwa, Suhail Allaqaband, Aurora Cardiovasc Svcs, Aurora Sinai/ St. Luke's Med Ctrs, Univ Wisconsin Sch Med & Public Health, Milwaukee, WI, USA, Center for Urban Population Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA*

Background: Data regarding patient understanding of the required continuation of clopidogrel dosing after percutaneous coronary intervention (PCI) are sparse. We attempted to identify the level of understanding/information patients have regarding usage of this drug after PCI. Our objective was to learn patient understanding about continuation of clopidogrel after elective PCI for treatment of coronary heart disease (CHD) in a contemporary clinical setting.

Methods: A cross-sectional survey of consecutive patients undergoing elective PCI for CHD at a tertiary care referral center was performed over 4 months. The standardized questionnaire included sections on demographic information, reason for PCI and information provided by hospital staff, including physicians, regarding clopidogrel usage post-PCI.

Results: The study cohort comprised 208 consecutive patients (median age 61 years, interquartile range 54-70 years; males 57%) undergoing PCI (with bare or drug-eluting stents) for CHD. Of 208 patients, 80% were non-Hispanic whites and 87% had some high school education. Awareness regarding the required continuation of clopidogrel usage post-PCI is depicted (figure).

Conclusions: Of patients who undergo PCI (stenting) for coronary heart disease in contemporary clinical practice, almost half are not fully aware of the time line for continuation of clopidogrel after implantation of either a bare-metal or a drug-eluting stent.

